Life Sciences

  • June 30, 2026

    Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims

    A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors before the IPO that its drug-development costs were high and rising, and therefore did not have to provide a quarter-by-quarter spending breakdown.

  • June 30, 2026

    Cellspin Settles Challenges To Its Patents At PTAB

    Three companies that challenged a series of Cellspin Soft Inc. patents for publishing data on websites have settled their disputes at the Patent Trial and Appeal Board after the board agreed to review the patents earlier this year.

  • June 30, 2026

    Pharma Co. Seeks Injunction Over Chinese Military Co. Label

    Chinese pharmaceutical company WuXi AppTec is urging a D.C. federal court judge to block the Pentagon from enforcing its designation of the company as a "Chinese military company," arguing the listing is unsupported by facts and was imposed without due process.

  • June 30, 2026

    Cigna, Others Fight Ohio AG's Drug Price-Fixing Suit

    Ohio pharmacy benefit managers and their corporate parents urged a federal judge to toss the state's drug price-fixing lawsuit, saying in a series of briefs that the state is trying to skirt federal pleading standards, collapse corporate separateness and stretch Ohio's antitrust law beyond its limits.

  • June 30, 2026

    ResMed Gets PTAB To Ax 1 Out Of 2 Sleep Apnea Patents

    The Patent Trial and Appeal Board has found that ResMed Corp. was able to prove claims in a Cleveland Medical Devices Inc. sleep apnea patent were invalid, but failed to prove the same on claims in another patent.

  • June 30, 2026

    Investor Sues In Chancery Over Alleged Sham Freeze-Out

    A minority investor in a medical technology company has sued its controlling stockholder in Delaware Chancery Court, accusing him of engineering a sham freeze-out merger that eliminated minority investors for pennies while diverting valuable intellectual property into companies he controlled.

  • June 30, 2026

    ITC Opens Patent Probe Into Chinese Protein Testing Co.

    The U.S. International Trade Commission said it has opened an investigation into a U.S. biotechnology company's claim that a Chinese company is importing and selling kits and other technology in the U.S. that infringe patents related to testing the proteins in genomes.

  • June 30, 2026

    High Court Sends 3 Roundup Cases Back After Monsanto Win

    The U.S. Supreme Court on Tuesday sent back several cases over claims that Bayer unit Monsanto Co.'s Roundup weed killer causes cancer, after the court last week delivered its ruling that state-based claims about a failure to warn on the weedkiller's labeling are barred by federal law.

  • June 29, 2026

    Wash. Panel Revives Claims Over Fertility Operation Injury

    A Washington appeals panel revived two claims against healthcare providers lodged by the family of a woman who suffered permanent brain damage as the result of an allergic reaction during an egg-retrieval procedure, ruling Monday that a lower court was wrong to toss the claims.

  • June 29, 2026

    26 States Sue To Nix Medicaid Work Rule For Medically Frail

    More than two dozen states sued the Trump administration Monday in Massachusetts federal court in a bid to strike down new Medicaid work requirements for certain enrollees, saying the administration did not consider the consequences the requirements would have on vulnerable Medicaid enrollees.

  • June 29, 2026

    AstraZeneca To Pay $34M In Texas Kickbacks Settlement

    AstraZeneca has agreed to pay nearly $34 million to the state of Texas to put to rest allegations the pharmaceutical company gave kickbacks to providers for prescribing its drugs, many of which were covered by the Lone Star State's Medicaid program, according to an announcement made Monday.

  • June 29, 2026

    Hospital That Halted Gender Care Must Show Cause

    A Colorado state court judge issued a citation on Friday to Children's Hospital Colorado ordering it to show cause for why the hospital refuses to provide gender-affirming care to patients in violation of a preliminary injunction order issued by the Colorado Supreme Court. 

  • June 29, 2026

    Sanofi Must Face Labeling Claims In Taxotere Eye Injury MDL

    A Louisiana federal judge won't let Sanofi escape claims in multidistrict litigation that it failed to properly warn about the risks and side effects of its chemotherapy drug Taxotere, saying the label is not so "accurate, clear and unambiguous" that it can be considered adequate as a matter of law.

  • June 29, 2026

    Insulin Makers Can't Nix 340B Antitrust Claims On Remand

    A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most of their state-law antitrust claims to survive but dismissing their unjust enrichment claims.

  • June 29, 2026

    Juvederm Users Say AbbVie Hid Risks Of Filler

    A putative class action filed in Illinois federal court claims AbbVie failed to adequately warn consumers that its Juvederm hyaluronic acid dermal fillers carry a significant risk of delayed-onset granulomas that can cause painful facial lumps, scarring and disfigurement.

  • June 29, 2026

    Ex-Sales Director Says Fortive Unit Used RIF To Mask Firing

    A former employee of a Fortive medical equipment subsidiary urged a Colorado federal judge to reject the unit and its parent's bid for an early win in her retaliation suit, saying evidence shows a restructuring masked her firing after she challenged government pricing violations.

  • June 29, 2026

    PBMs Drop Fight To Pause Insulin Case Amid Deal Talks

    Optum, Caremark and Express Scripts on Monday dropped their appeal in a case challenging the constitutionality of the Federal Trade Commission's in-house administrative process, and the pharmacy benefit managers are working to settle the commission's remaining insulin-pricing claims.

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 29, 2026

    Supreme Court Shuts Down 4 Patent Cases

    The U.S. Supreme Court turned down four petitions over patent law Monday, meaning it won't review questions related to prosecution laches, jury verdicts, patent eligibility and marking.

  • June 26, 2026

    4 Takeaways From The High Court's Monsanto Ruling

    The U.S. Supreme Court's highly anticipated ruling in favor of Monsanto over its blockbuster pesticide Roundup established that a pesticide's labeling must meet federal standards, ensuring that businesses don't have to comply with a variety of potentially conflicting state laws.

  • June 26, 2026

    PACER Fees Will Rise To Fund Cyber Defense Upgrades

    The federal judiciary announced Friday it will temporarily increase the fees for electronic access to court records to pay for a potential $800 million upgrade that will modernize and strengthen court records systems PACER and CM/ECF, an upgrade it previously said is needed to respond to escalating cyberattacks.

  • June 26, 2026

    Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit

    Pfizer defeated a former employee's whistleblower retaliation suit Friday after a California federal judge ruled the "uncontroverted material facts" show the company would have fired him for "legitimate, independent reasons" even if he did engage in protected whistleblowing.

  • June 26, 2026

    Endoscopy Device Maker's Trade Secret Suit Trimmed In Ohio

    An Ohio federal judge has kept alive most of medical equipment supplier Steris' lawsuit claim that a former research and development director stole its intellectual property to form a competitor, but agreed to trim some claims in the case.

  • June 26, 2026

    DC Circ. Affirms FDA Can Block Norwich's IBS Generic

    The D.C. Circuit on Friday backed the U.S. Food and Drug Administration's lower court win in Norwich Pharmaceuticals' challenge to the agency's refusal to approve an application to bring a generic version of a prescription antibiotic for irritable bowel syndrome to market until 2029.

  • June 26, 2026

    EU Probing Sanofi For Disparaging Rival Flu Vaccine

    European enforcers are investigating whether Sanofi used a messaging campaign directed mainly at healthcare professionals in Germany and France to disparage the only rival flu vaccine recommended for vulnerable patients.

Expert Analysis

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

  • Unpacking Dormant Commerce Clause Cannabis Circuit Split

    Author Photo

    Federal courts have reached differing conclusions as to whether state-legal cannabis is subject to the dormant commerce clause, with four opinions across three circuit courts in the last year demonstrating the continued salience of the dormant commerce clause debate to the nation's cannabis industry, regulators and policymakers, say attorneys at Perkins Coie.

  • Opinion

    CFIUS Must Adapt To Current Foreign Investment Realities

    Author Photo

    To continue protecting the U.S.’ long-term strategic and economic interests, the Committee on Foreign Investment in the United States should implement practical enhancements that leverage technology, expertise and clear communication, and enable it to keep pace with evolving demands, says attorney Sohan Dasgupta.

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

  • From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination

    Author Photo

    With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.

  • Series

    Law School's Missed Lessons: Practicing Resilience

    Author Photo

    Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.

  • Takeaways From The DOJ Fraud Section's 2025 Year In Review

    Author Photo

    Former acting Principal Deputy Chief Sean Tonolli of the U.S. Department of Justice's Fraud Section, now at Cahill Gordon, analyzes key findings from the section’s annual report — including the changes implemented to adapt to the new administration’s priorities — and lays out what to watch for this year.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.